Alcohol can enhance the blood-pressure-lowering effect of avanafil and may increase dizziness from dapoxetine. Moderation is advised, and if you experience light-headedness, avoid further alcohol until the effect subsides.
A prolonged erection (priapism) is a medical emergency. Seek immediate care at the nearest emergency department; early treatment reduces the risk of permanent tissue damage.
Pharmacologically they contain the same active amounts, but the combination pill is not formally authorised in the UK. Substituting with individually approved tablets is acceptable under a prescriber’s guidance.
A high-fat meal may delay avanafil’s onset of action. Taking the pill with a light meal or on an empty stomach can help achieve the expected timing.
Avanafil typically provides erectile support for up to 6 hours, while dapoxetine’s effect on ejaculation latency lasts roughly 2-3 hours after ingestion. The combination aims to cover the window needed for most sexual encounters.
Super Avana is indicated for adult men with erectile dysfunction and/or premature ejaculation. Its safety and efficacy have not been established in women.
Both avanafil and dapoxetine can lower blood pressure. When combined with antihypertensives, especially alpha-blockers, there is an increased risk of symptomatic hypotension. Blood pressure should be monitored and doses adjusted if necessary.
Both avanafil and dapoxetine are available as generic products in the UK. A fixed-dose generic combination has not been marketed; clinicians may prescribe the two generic tablets separately.
If you experience dizziness, light-headedness, or visual disturbances after taking the medication, you should refrain from driving or operating heavy machinery until you feel fully recovered.
Keep the tablets in their original container, protected from heat, humidity, and direct sunlight. Avoid extreme temperatures (e.g., leaving them in a car on a hot day) and consider a travel-approved medication case.
Super Avana is a combination pill that contains two active ingredients: avanafil (a phosphodiesterase-5 inhibitor) and dapoxetine (a short-acting selective serotonin-reuptake inhibitor). The tablet is formulated as a 100 mg avanafil / 60 mg dapoxetine pill and is intended for oral use.
Avanafil selectively blocks the enzyme phosphodiesterase-5 (PDE5) in the erectile tissue of the penis. By preventing the breakdown of cyclic guanosine monophosphate (cGMP), avanafil allows cGMP to accumulate when sexual stimulation triggers nitric-oxide release. The higher cGMP level relaxes smooth muscle, increasing blood flow and producing an erection. Avanafil has a rapid onset of action (≈30 minutes) and a relatively short duration compared with older PDE5 inhibitors.
Dapoxetine inhibits the re-uptake of serotonin (5-HT) at central synapses, enhancing serotonergic neurotransmission. The increased serotonin activity delays the ejaculatory reflex, extending the latency time between stimulation and orgasm. Dapoxetine’s half-life (≈1-2 hours) makes it suitable for on-demand use before sexual activity, unlike traditional SSRIs that require daily dosing.
When taken together, avanafil facilitates the physiological process needed for an erection, while dapoxetine prolongs the ejaculatory interval. Theoretically, the combination addresses both the ability to achieve an erection and the capacity to maintain sexual performance for a satisfactory duration in a single pill.
| Ingredient | MHRA-Approved Indication(s) | Typical Patient Population | ||-|-| | Avanafil | Erectile dysfunction (moderate to severe) | Adult men who can achieve sexual stimulation | | Dapoxetine | Premature ejaculation (lifelong or acquired) | Adult men whose intravaginal ejaculatory latency time (IELT) is ≤ 1-2 minutes and who desire longer control |
Super Avana does not have a separate MHRA approval for the combined treatment of ED + PE. Physicians may prescribe the individual components separately, and in some clinical settings the combination may be used off-label when both conditions coexist.
The simultaneous use of a PDE5 inhibitor with dapoxetine to treat co-existing ED and PE has been explored in a limited number of clinical studies. Evidence suggests that treating both mechanisms can improve overall sexual satisfaction, but robust, large-scale randomised trials are lacking.
| Population | Considerations | ||-| | Pregnant or breastfeeding men | Not applicable; however, partners should be advised that dapoxetine passes into breast milk. | | Elderly (≥ 65 years) | Start with the lowest effective dose; monitor for hypotension, falls, and drug-drug interactions. | | Patients with hepatic disease | Use with caution; consider dose reduction of dapoxetine. | | Patients on antidepressants | Assess for additive serotonergic effects; avoid combining with other SSRIs or SNRIs without specialist input. |
| Interaction | Effect | Management | |-|--|| | CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) | ↑ avanafil plasma levels → increased hypotensive risk | Avoid or reduce avanafil dose. | | CYP2D6 inhibitors (e.g., fluoxetine) | ↑ dapoxetine levels → heightened serotonergic side effects | Consider alternative antidepressant or adjust dapoxetine dose. | | Alpha-blockers (e.g., tamsulosin) | Additive blood pressure lowering | Monitor BP; dose titration may be needed. | | Other SSRIs/SNRIs | Risk of serotonin syndrome | Use dapoxetine alone; avoid concurrent serotonergic drugs. | | Anticoagulants (e.g., warfarin) | No direct pharmacokinetic interaction, but caution if bleeding risk is elevated due to hypotension. | Routine monitoring of INR. |
Regular follow-up every 3-6 months (or sooner if adverse effects arise) is advisable.
This article provides educational information about Super Avana and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
